SATELLOS Announces Proposed Non-Brokered Offerings Of Unsecured Non-Convertible Debentures of up to $2.25 Million
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos’
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 as a Potential Treatment for Duchenne
Satellos Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
- SAT-3153 Designated for pre-IND Studies - TORONTO, January 03, 2023 – Satellos Bioscience Inc.
SATELLOS BIOSCIENCE ANNOUNCES Q3 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS TORONTO, November 23, 2022 –
-Proof of concept studies to be completed by YE- TORONTO, November 03, 2022 – Satellos
Satellos Bioscience Inc. to present preliminary preclinical proof of concept data for an additional rare
TORONTO, October 6, 2022 – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Corporation”), is
SATELLOS BIOSCIENCE ANNOUNCES OTCQB LISTING IN THE UNITED STATES TORONTO, October 6, 2022 – Satellos